前列腺癌患者第二原发癌的研究进展
|
摘要
前列腺癌是男性患者中发病率第二的肿瘤,且随着科技的发展,对前列腺癌的诊断和治疗手段越来越先进,显著延长了患者的生存时间,改善了患者的生存质量,从而也使得许多前列腺癌患者被检出继发第二原发癌。本文对前列腺癌患者常见的第二原发癌及第二原发癌的病因、诊断、治疗和预后相关方面的研究进展予以综述,为该疾病的临床防治提供参考。
Prostate cancer is a common cancer among male patients. With the development of science and technology, the diagnosis and treatment of prostate cancer are becoming more and more advanced, which significantly extends the survival time of patients and improves their quality of life, so that many prostate cancer patients are diagnosed with secondary primary cancer. This paper reviews the general situation,etiology, diagnosis, treatment and prognosis of the second primary cancer in prostate cancer patients.
Prostate cancer is a common cancer among male patients. With the development of science and technology, the diagnosis and treatment of prostate cancer are becoming more and more advanced, which significantly extends the survival time of patients and improves their quality of life, so that many prostate cancer patients are diagnosed with secondary primary cancer. This paper reviews the general situation,etiology, diagnosis, treatment and prognosis of the second primary cancer in prostate cancer patients.
引文
[1]Warren S,Gates O.Multiple primary malignant tumors:a survey of the literature and statistical study[J].Am J Cancer,1932,16:1358-414.
[2]Chen T,Fallah M,Jansen L,et al.Distribution and risk of the second discordant primary cancers combined after a specific first primary cancer in German and Swedish cancer registries[J].Cancer Lett,2015,369(1):152-66.
[3]Riihimaki M,Thomsen H,Brandt A,et al.What do prostate cancer patients die of?[J].Oncologist,2011,16(2):175-81.
[4]Wood ME,Vogel V,Ng A,et al.Second malignant neoplasms:assessment and strategies for risk reduction[J].J Clin Oncol,2012,30(30):3734-45.
[5]Schaapveld M,Aleman BM,van Eggermond AM,et al.Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma[J].N Engl J Med,2015,373(26):2499-511.
[6]Travis LB,Demark Wahnefried W,Allan JM,et al.Aetiology,genetics and prevention of secondary neoplasms in adult cancer survivors[J].Nat Rev Clin Oncol,2013,10(5):289-301.
[7]Chattopadhyay S,Zheng G,Hemminki O,et al.Prostate cancer survivors:Risk and mortality in second primary cancers[J].Cancer Med,2018,7(11):5752-9.
[8]Torre LA,Bray F,Siegel RL,et al.Global Cancer Statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[9]Mariotto AB,Rowland JH,Ries LA,et al.Multiple cancer prevalence:a growing challenge in long-term survivorship[J].Cancer Epidemiol Biomarkers Prev,2007,16(3):566-71.
[10]Desautels D,Czaykowski P,Nugent Z,et al.Risk of colorectal cancer after the diagnosis of prostate cancer:A population-based study[J].Cancer,2016,122(8):1254-60.
[11]Vogt A,Schmid S,Heinimann K,et al.Multiple primary tumours:challenges and approaches,a review[J].ESMO Open,2017,2(2):e000172.
[12]Travis LB,Demark Wahnefried W,Allan JM,et al.Aetiology,genetics and prevention of secondary neoplasms in adult cancer survivors[J].Nat Rev Clin Oncol,2013,10(5):289-301.
[13]Davis EJ,Beebe-Dimmer JL,Yee CL,et al.Risk of second primary tumors in men diagnosed with prostate cancer:a population-based cohort study[J].Cancer,2014,120(17):2735-41.
[14]Jin T,Song T,Deng S,et al.Radiation-induced secondary malignancy in prostate cancer:a systematic review and metaanalysis[J].Urol Int,2014,93(3):279-88.
[15]Lu Y,Ljung R,Martling A,et al.Risk of Colorectal Cancer by Subsite in a Swedish Prostate Cancer Cohort[J].Cancer Control,2015,22(2):263-70.
[16]Jung K,Park JC,Kang H,et al.Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer[J].Epidemiol Health,2018:40:e2018040.
[17]Fan CY,Huang WY,Lin CS,et al.Risk of second primary malignancies among patients with prostate cancer:A populationbased cohort study[J].PLoS One,2017,12(4):e0175217.
[18]Cano-Velasco J,Herranz-Amo F,Barbas-Bernardos G,et al.Incidence of second tumours in high risk prodtate cancer patients according to the primary treatment applied[J].Actas Urol Esp,2019,43(1):18-25.
[19]Moschini M,Zaffuto E,Karakiewicz PI,et al.External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer:A Population-based Analysis[J].Eur Urol,2019,75(2):319-28.
[20]Joung JY,Lim J,Oh CM,et al.Risk of Second Primary Cancer among Prostate Cancer Patients in Korea:A Population-Based Cohort Study[J].PLoS One,2015,10(10):e0140693.
[21]Nieder AM,Porter MP,Soloway MS,et al.Radiation Therapy for Prostate Cancer Increases Subsequent Risk of Bladder and Rectal Cancer:A Population Based Cohort Study[J].J Urol,2008,180(5):2005-9.
[22]Murray L,Henry A,Hoskin P,et al.Second primary cancers after radiation for prostate cancer:a systematic review of the clinical data and impact of treatment technique[J].Radiother Oncol,2014,110(2):213-28.
[23]Krasnow RE,Rodriguez D,Nagle RT,et al.The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies[J].Urol Oncol,2018,36(11):e11-500.e19.
[24]Berrington de Gonzalez A,Curtis RE,Kry SF,et al.Proportion of second cancers attributable to radiotherapy treatment in adults:a cohort study in the US SEER cancer registries[J].Lancet Oncol,2011,12(4):353-60.
[25]Bosco C,Garmo H,Hammar N,et al.Glucose,lipids and gammaglutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours:a prospective study in the Swedish AMORIS cohort[J].BMC Cancer,2018,18(1):205.
[26]Chattopadhyay S,Hemminki O,Forsti A,et al.Impact of family history of cancer on risk and mortality of second cancers in patients with prostate cancer[J].Prostate Cancer Prostatic Dis,2019,22(1):143-9.
[27]Gottschalk A.Commentary on“Secondary cancers after intensitymodulated radiotherapy,brachytherapy,and radical prostatectomy for the treatment of prostate cancer:Incidence and causespecific survival outcomes according to the initial treatment intervention[J].Urol Oncol,2014,32(2):209.
[28]Park SL,Caberto CP,Lin Y,et al.Association of cancer susceptibility variants with risk of multiple primary cancers:the population architecture using genomics and epidemiology study[J].Cancer Epidemiol Biomarkers Prev,2014,23(11):2568-78.
[29]孙俊杰,李双庆.多原发癌病因及发病机制的探索[J].中国全科医学,2017,20(9):1136-41.[Sun JJ,Li SQ.Exploration of etiology and pathogenesis of multiple malignant neoplasms[J].Zhongguo Quan Ke Yi Xue,2017,20(9):1136-41.
[30]Powell S,Tarchand G,Rector T,et al.Synchronous and metachronous malignancies:analysis of the Minneapolis Veterans Affairs(VA)tumor registry[J].Cancer Causes Control,2013,24(8):1565-73.
[2]Chen T,Fallah M,Jansen L,et al.Distribution and risk of the second discordant primary cancers combined after a specific first primary cancer in German and Swedish cancer registries[J].Cancer Lett,2015,369(1):152-66.
[3]Riihimaki M,Thomsen H,Brandt A,et al.What do prostate cancer patients die of?[J].Oncologist,2011,16(2):175-81.
[4]Wood ME,Vogel V,Ng A,et al.Second malignant neoplasms:assessment and strategies for risk reduction[J].J Clin Oncol,2012,30(30):3734-45.
[5]Schaapveld M,Aleman BM,van Eggermond AM,et al.Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma[J].N Engl J Med,2015,373(26):2499-511.
[6]Travis LB,Demark Wahnefried W,Allan JM,et al.Aetiology,genetics and prevention of secondary neoplasms in adult cancer survivors[J].Nat Rev Clin Oncol,2013,10(5):289-301.
[7]Chattopadhyay S,Zheng G,Hemminki O,et al.Prostate cancer survivors:Risk and mortality in second primary cancers[J].Cancer Med,2018,7(11):5752-9.
[8]Torre LA,Bray F,Siegel RL,et al.Global Cancer Statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[9]Mariotto AB,Rowland JH,Ries LA,et al.Multiple cancer prevalence:a growing challenge in long-term survivorship[J].Cancer Epidemiol Biomarkers Prev,2007,16(3):566-71.
[10]Desautels D,Czaykowski P,Nugent Z,et al.Risk of colorectal cancer after the diagnosis of prostate cancer:A population-based study[J].Cancer,2016,122(8):1254-60.
[11]Vogt A,Schmid S,Heinimann K,et al.Multiple primary tumours:challenges and approaches,a review[J].ESMO Open,2017,2(2):e000172.
[12]Travis LB,Demark Wahnefried W,Allan JM,et al.Aetiology,genetics and prevention of secondary neoplasms in adult cancer survivors[J].Nat Rev Clin Oncol,2013,10(5):289-301.
[13]Davis EJ,Beebe-Dimmer JL,Yee CL,et al.Risk of second primary tumors in men diagnosed with prostate cancer:a population-based cohort study[J].Cancer,2014,120(17):2735-41.
[14]Jin T,Song T,Deng S,et al.Radiation-induced secondary malignancy in prostate cancer:a systematic review and metaanalysis[J].Urol Int,2014,93(3):279-88.
[15]Lu Y,Ljung R,Martling A,et al.Risk of Colorectal Cancer by Subsite in a Swedish Prostate Cancer Cohort[J].Cancer Control,2015,22(2):263-70.
[16]Jung K,Park JC,Kang H,et al.Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer[J].Epidemiol Health,2018:40:e2018040.
[17]Fan CY,Huang WY,Lin CS,et al.Risk of second primary malignancies among patients with prostate cancer:A populationbased cohort study[J].PLoS One,2017,12(4):e0175217.
[18]Cano-Velasco J,Herranz-Amo F,Barbas-Bernardos G,et al.Incidence of second tumours in high risk prodtate cancer patients according to the primary treatment applied[J].Actas Urol Esp,2019,43(1):18-25.
[19]Moschini M,Zaffuto E,Karakiewicz PI,et al.External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer:A Population-based Analysis[J].Eur Urol,2019,75(2):319-28.
[20]Joung JY,Lim J,Oh CM,et al.Risk of Second Primary Cancer among Prostate Cancer Patients in Korea:A Population-Based Cohort Study[J].PLoS One,2015,10(10):e0140693.
[21]Nieder AM,Porter MP,Soloway MS,et al.Radiation Therapy for Prostate Cancer Increases Subsequent Risk of Bladder and Rectal Cancer:A Population Based Cohort Study[J].J Urol,2008,180(5):2005-9.
[22]Murray L,Henry A,Hoskin P,et al.Second primary cancers after radiation for prostate cancer:a systematic review of the clinical data and impact of treatment technique[J].Radiother Oncol,2014,110(2):213-28.
[23]Krasnow RE,Rodriguez D,Nagle RT,et al.The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies[J].Urol Oncol,2018,36(11):e11-500.e19.
[24]Berrington de Gonzalez A,Curtis RE,Kry SF,et al.Proportion of second cancers attributable to radiotherapy treatment in adults:a cohort study in the US SEER cancer registries[J].Lancet Oncol,2011,12(4):353-60.
[25]Bosco C,Garmo H,Hammar N,et al.Glucose,lipids and gammaglutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours:a prospective study in the Swedish AMORIS cohort[J].BMC Cancer,2018,18(1):205.
[26]Chattopadhyay S,Hemminki O,Forsti A,et al.Impact of family history of cancer on risk and mortality of second cancers in patients with prostate cancer[J].Prostate Cancer Prostatic Dis,2019,22(1):143-9.
[27]Gottschalk A.Commentary on“Secondary cancers after intensitymodulated radiotherapy,brachytherapy,and radical prostatectomy for the treatment of prostate cancer:Incidence and causespecific survival outcomes according to the initial treatment intervention[J].Urol Oncol,2014,32(2):209.
[28]Park SL,Caberto CP,Lin Y,et al.Association of cancer susceptibility variants with risk of multiple primary cancers:the population architecture using genomics and epidemiology study[J].Cancer Epidemiol Biomarkers Prev,2014,23(11):2568-78.
[29]孙俊杰,李双庆.多原发癌病因及发病机制的探索[J].中国全科医学,2017,20(9):1136-41.[Sun JJ,Li SQ.Exploration of etiology and pathogenesis of multiple malignant neoplasms[J].Zhongguo Quan Ke Yi Xue,2017,20(9):1136-41.
[30]Powell S,Tarchand G,Rector T,et al.Synchronous and metachronous malignancies:analysis of the Minneapolis Veterans Affairs(VA)tumor registry[J].Cancer Causes Control,2013,24(8):1565-73.